Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ofer Agid

Showing results (11-20 of 128) with videos related to

Pageof 13
Sort By:
Expert Opinion on Pharmacotherapy|July 1, 2010
Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse preventionOfer Agid, George Foussias, Gary Remington
Expert Review of Neurotherapeutics|April 8, 2011
Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatmentGary Remington, Ofer Agid, George Foussias
Focus (American Psychiatric Publishing)|November 20, 2024
Renal Impairment and Dose Adjustment of Long-Acting Injectable Antipsychotics: Are We Getting It Right? A Case ReportColette Raphaël, Gary Remington, Ofer Agid
Expert Opinion on Emerging Drugs|September 4, 2008
Emerging drugs for schizophreniaOfer Agid, Shitij Kapur, Gary Remington
CNS Drugs|December 25, 2009
Progress in defining optimal treatment outcome in schizophreniaGary Remington, George Foussias, Ofer Agid
JAMA Psychiatry|May 7, 2015
Measuring the effects of treatment with antipsychoticsCynthia O Siu, Ofer Agid, Gary Remington
Schizophrenia (Heidelberg, Germany)|December 17, 2025
Antipsychotic discontinuation in schizophrenia: rational or reckless?Robert B Zipursky, Ofer Agid, Gary Remington
Lancet (London, England)|December 10, 2013
Efficacy of antipsychotic drugs for schizophreniaCynthia O Siu, Ofer Agid, Gary Remington
The Lancet. Psychiatry|April 28, 2018
Improving outcomes in schizophrenia by preventing early relapsesRobert B Zipursky, Ofer Agid, Gary Remington
Schizophrenia Research|December 17, 2013
Effect of intrinsic motivation on cognitive performance in schizophrenia: a pilot studyGagan Fervaha, Ofer Agid, George Foussias, et al.
Pageof 13

Showing results (11-20 of 128) with videos related to

Sort By:
Pageof 13
Expert Opinion on Pharmacotherapy|July 1, 2010
Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse preventionOfer Agid, George Foussias, Gary Remington
Expert Review of Neurotherapeutics|April 8, 2011
Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatmentGary Remington, Ofer Agid, George Foussias
Focus (American Psychiatric Publishing)|November 20, 2024
Renal Impairment and Dose Adjustment of Long-Acting Injectable Antipsychotics: Are We Getting It Right? A Case ReportColette Raphaël, Gary Remington, Ofer Agid
Expert Opinion on Emerging Drugs|September 4, 2008
Emerging drugs for schizophreniaOfer Agid, Shitij Kapur, Gary Remington
CNS Drugs|December 25, 2009
Progress in defining optimal treatment outcome in schizophreniaGary Remington, George Foussias, Ofer Agid
JAMA Psychiatry|May 7, 2015
Measuring the effects of treatment with antipsychoticsCynthia O Siu, Ofer Agid, Gary Remington
Schizophrenia (Heidelberg, Germany)|December 17, 2025
Antipsychotic discontinuation in schizophrenia: rational or reckless?Robert B Zipursky, Ofer Agid, Gary Remington
Lancet (London, England)|December 10, 2013
Efficacy of antipsychotic drugs for schizophreniaCynthia O Siu, Ofer Agid, Gary Remington
The Lancet. Psychiatry|April 28, 2018
Improving outcomes in schizophrenia by preventing early relapsesRobert B Zipursky, Ofer Agid, Gary Remington
Schizophrenia Research|December 17, 2013
Effect of intrinsic motivation on cognitive performance in schizophrenia: a pilot studyGagan Fervaha, Ofer Agid, George Foussias, et al.
Pageof 13